Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
16.04.2016 20:12:01

NY Attorney General Sues CDPHP For Unlawfully Denying Coverage Of HCV Treatment

(RTTNews) - New York Attorney General Eric Schneiderman has filed a lawsuit against health insurer Capital District Physician's Health Plan for unlawfully denying coverage of Hepatitis C treatment. The lawsuit alleges that CDPHP denied coverage for HCV treatment unless the member demonstrated advanced disease. The lawsuit further alleges that by failing to fully disclose the definition of "medically necessary" used in determining when benefits will be covered, CDPHP is violating the New York State Insurance Law and Public Health Law.

Attorney General Schneiderman said: "Forcing patients to wait for care, risking internal organ damage, is unconscionable and, as we allege in our lawsuit, violates the law and the company's own policies."

CDPHP has approximately 450,000 members in New York State and provides service to 24 counties throughout the Capital Region, North Country, Hudson Valley, Central New York, and the Southern Tier.

The statement from A.G. Schneiderman noted that the lawsuit is part of a continuing investigation into numerous health insurers for improperly restricting coverage of Hepatitis C treatments.

Analysen zu Pfizer Inc.mehr Analysen

14.11.24 Pfizer Neutral UBS AG
01.11.24 Pfizer Neutral UBS AG
30.10.24 Pfizer Buy Goldman Sachs Group Inc.
29.10.24 Pfizer Buy Jefferies & Company Inc.
24.10.24 Pfizer Neutral JP Morgan Chase & Co.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

AbbVie Inc 169,48 3,33% AbbVie Inc
Enanta Pharmaceuticals Inc 8,85 1,14% Enanta Pharmaceuticals Inc
Merck Co. 95,10 0,00% Merck Co.
Novartis AG (Spons. ADRS) 99,60 2,05% Novartis AG (Spons. ADRS)
Pfizer Inc. 24,55 2,85% Pfizer Inc.